Pet industry M&A activity picks up again this winter
A fresh round of mergers and acquisitions is moving through the pet industry this winter, touching everything from premium pet food brands to service marketplaces and veterinary distribution. The pattern matches what GlobalPETS flagged in its winter roundup: companies are using acquisitions and mergers to extend geographic reach, add capabilities, and deepen their hold on higher-growth parts of the market. Recent announcements suggest that momentum has carried into early 2026, particularly in Europe and North America. (globalpetindustry.com)
The backdrop is a market that had slowed before showing signs of reopening. PetfoodIndustry reported in December 2024 that Cascadia Capital expected a resurgence in pet-sector M&A in 2025, citing easing rates, unused private equity capital, and a limited but valuable pool of attractive targets. By January 2026, PetfoodIndustry said analysts were seeing the start of a more active phase, with dealmaking likely to become more complex rather than simply more frequent. GlobalPETS also reported in March 2026 that pet investment cooled in 2025 overall, with PitchBook logging 262 venture capital and acquisition deals worth about $899.5 million globally, even as advisers forecast more sponsor exits and renewed transaction flow in 2026. (petfoodindustry.com)
One of the clearest new examples is AlphaPet’s acquisition of Cpro Food, announced March 27, 2026. AlphaPet described Cpro Food as a Belgian super-premium brand and said the deal is its fifth acquisition since 2020, fitting its “buy-and-build” strategy around local premium brands in Europe. Elsewhere in pet food, PetfoodIndustry reported that Spain’s Agrolimen acquired fresh dog food brand Ollie on February 6, 2026, while other February deals included Pure Treats’ acquisition of Primal Pet Foods and Nasta Pet Food’s acquisition of FirstMate Pet Foods. Taken together, those moves suggest buyers remain especially interested in premium, fresh, raw, and differentiated nutrition brands. (ad-hoc-news.de)
On the veterinary side, the most consequential development may be the planned merger of Covetrus and MWI Animal Health, announced February 18, 2026, by Cencora and Covetrus. The companies said the combined business would bring together MWI’s distribution footprint and Covetrus’ technology and services platform, aiming to create a broader animal health offering for veterinarians, producers, dealers, manufacturers, distributors, and pet parents. That follows other major animal health distribution consolidation, including Patient Square Capital’s acquisition of Patterson Companies, which closed on April 17, 2025, in a deal valued at about $4.1 billion. Meanwhile, Blackstone’s Rover acquisition shows that investor interest still extends beyond products and into consumer-facing care platforms with large pet parent audiences. (covetrus.com)
Industry commentary has been notably measured rather than euphoric. PetfoodIndustry said experts were “cautiously optimistic” on 2026 M&A prospects, while Cascadia’s winter outlook pointed to continuing demand and healthy valuations for businesses with strong fundamentals and growth potential. That tone matters: buyers appear willing to do deals, but they’re being selective, and the assets drawing attention tend to be brands or platforms with clear positioning, scale potential, or infrastructure value. In other words, this looks less like indiscriminate consolidation and more like targeted portfolio building. (petfoodindustry.com)
Why it matters: For veterinary professionals, the practical effects could show up in supply chain relationships, software ecosystems, pharmacy workflows, and pet parent expectations. If large distributors and practice technology providers continue to combine, clinics could eventually see broader bundled offerings, stronger logistics, and potentially fewer major partners to choose from. At the same time, more consolidation in premium food and direct-to-consumer services may strengthen the consumer brands pet parents already know before they ever walk into a clinic. That can create both opportunities and pressure: opportunities if better logistics and connected tools reduce friction, and pressure if consolidation narrows options or shifts pricing power upstream. The proposed Covetrus-MWI merger is particularly worth watching because its stated rationale is explicitly clinic-facing, centered on efficiency, logistics, and practice support. (covetrus.com)
What to watch: The next question is whether winter’s announcements become a sustained 2026 pattern, and whether regulators, integration timelines, and financing conditions allow buyers to follow through. Veterinary teams should watch for approval milestones on the Covetrus-MWI deal, signs of operational integration at recently acquired companies, and whether more distributors, diagnostics businesses, or pet health platforms come to market as sponsors pursue exits in what advisers increasingly describe as a more open deal environment. (covetrus.com)